Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

Reid, DM; Devogelaer, JP; Saag, K; Roux, C; Lau, CS; Reginster, JY; Papanastasiou, P; Ferreira, A; Hartl, F; Fashola, T; Mesenbrink, P; Sambrook, PN; Perrelet, Romain; HORIZON, investigators (2009). Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet, 373(9671), pp. 1253-1263. London: Elsevier 10.1016/S0140-6736(09)60250-6

Full text not available from this repository. (Request a copy)

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Orthopaedic, Plastic and Hand Surgery (DOPH) > Clinic of Osteoporosis

UniBE Contributor:

Perrelet, Romain

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0140-6736

Publisher:

Elsevier

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:13

Last Modified:

08 Jun 2016 10:54

Publisher DOI:

10.1016/S0140-6736(09)60250-6

Web of Science ID:

000265146300028

URI:

https://boris.unibe.ch/id/eprint/32401 (FactScience: 197558)

Actions (login required)

Edit item Edit item
Provide Feedback